These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 18629356

  • 21. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.
    Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.
    J Lipid Res; 2017 Nov; 58(11):2180-2187. PubMed ID: 28928170
    [Abstract] [Full Text] [Related]

  • 22. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
    Wierzbicki AS.
    Curr Opin Cardiol; 2009 Jul; 24(4):372-9. PubMed ID: 19424060
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Dohmen K, Tanaka H, Haruno M.
    Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
    [Abstract] [Full Text] [Related]

  • 27. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy.
    Fazio S, Linton MF.
    Curr Atheroscler Rep; 2004 Mar; 6(2):148-57. PubMed ID: 15023300
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [Abstract] [Full Text] [Related]

  • 30. Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting.
    Ramachandran S, Abbas A, Saraf S, Raju J, Jewkes C, Jones AF.
    Metab Syndr Relat Disord; 2012 Jun; 10(3):189-94. PubMed ID: 22283634
    [Abstract] [Full Text] [Related]

  • 31. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV.
    Am J Cardiovasc Drugs; 2008 Jun; 8(4):243-55. PubMed ID: 18690758
    [Abstract] [Full Text] [Related]

  • 32. [Fibrates in the secondary prevention of ischemic cardiopathy].
    Posadas Romero C.
    Arch Cardiol Mex; 2001 Jun; 71 Suppl 1():S139-41. PubMed ID: 11565320
    [Abstract] [Full Text] [Related]

  • 33. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM, Croom KF.
    Drugs; 2007 Jun; 67(1):121-53. PubMed ID: 17209672
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
    Wierzbicki AS.
    Curr Opin Lipidol; 2010 Aug; 21(4):352-8. PubMed ID: 20625256
    [Abstract] [Full Text] [Related]

  • 37. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
    Roglans N, Bellido A, Rodríguez C, Cabrero A, Novell F, Ros E, Zambón D, Laguna JC.
    Clin Pharmacol Ther; 2002 Dec; 72(6):692-701. PubMed ID: 12496750
    [Abstract] [Full Text] [Related]

  • 38. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
    Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T.
    J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
    [Abstract] [Full Text] [Related]

  • 39. Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.
    Linton MF, Fazio S.
    Curr Atheroscler Rep; 2000 Jan; 2(1):29-35. PubMed ID: 11122722
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.